CARsgen Therapeutics Holdings Limited reported a net increase of 40,500 ordinary shares for March 2026, lifting its issued share count (excluding treasury stock) to 570.35 million. Treasury shares remained unchanged at 7.82 million, keeping total issued shares at 578.17 million.
Authorised capital was steady at 200.00 billion ordinary shares with a par value of USD 0.00000025, equivalent to USD 50,000.
Share-based incentives drove the month’s issuance: • Post-IPO Share Option Scheme – 4.27 million options were granted, 34,500 options were exercised (all settled via new share issuance), and 126,000 lapsed. Outstanding options rose to 18.66 million, while the scheme’s maximum potential issuance stands at 23.49 million shares. Exercises generated HKD 0.59 million in proceeds. • 2019 Equity Incentive Plan – 6,000 new shares were issued; 2.32 million shares remain available for future grants. • No activity occurred under the Post-IPO RSU Scheme during the month.
Repurchase activity previously disclosed left 455,000 shares bought back in October 2025 still pending cancellation as of 31 March 2026; no new buybacks or treasury share movements were recorded in March.
CARsgen confirmed compliance with the Main Board’s minimum 25% public-float requirement, and no warrants or convertible securities were outstanding or exercised during the period.
Comments